Paracetamol is thought that it acts by inhibiting the central cyclooxygenase (COX) enzyme; its mechanism of action is still not fully explained. Although its most important side effect is hepatoxicity, it is thought to cause toxicity on the brain in recent years. The present study aims to investigate the treatment and toxic effects of low and high doses of paracetamol on the liver and brain. Wistar-albino rats were used in this study. At doses of 20–500 mg/kg, paracetamol was administered intraperitoneally once a day for one and three days. The brain and liver were used for immunohistochemical evaluation using COX-3, prostaglandin E2 (PGE2) and caspase 3 antibodies and for total antioxidant (TAS), total oxidant (TOS) and oxidative stress index (OSI) measurements. Results were evaluated using the Kruskal Wallis test (SPSS ver.24). The liver COX-3 levels were significantly lower in both groups with higher doses (p0.05). The caspase 3 level in the liver was statistically significantly higher in the low dose group compared to the other groups (p0.05). The results of our study show that paracetamol inhibits the COX-3 enzyme in the liver but has no effect in the brain, and COX-3 does not have an effect on PGE2. Paracetamol causes apoptosis in the liver only in low doses; higher doses may cause toxicity by increasing oxidative stress, especially in the brain.
Gastric and esophageal cancers are 2 of the most prevalent cancer types worldwide. Polymorphisms in the genes that code the methylenetetrahydrofolate reductase (MTHFR) enzyme increase the formation of both cancer types. In this study, it was aimed to research the relationship between the existence of MTHFRC677T and A1298C polymorphisms in patients with gastric and esophageal cancer and the lifespans of patients. This prospective study was performed at Van Yuzuncu Yil University. Included in the study were 30 patients with esophageal tumors, 70 patients with gastric tumors, and 61 healthy volunteers. From each of the patients, 5 mL of blood was drawn. DNA was isolated via kits with spin-column technology. It was concluded that the risk of developing gastric cancer was 4.13 times higher in individuals who had the AC genotype of the A1298C polymorphism when compared to those who had the AA genotype, while the risk was 2.91 times higher in individuals who had the CC genotype when compared to those who had the AA genotype (P = 0.001, P = 0.027). Carriers of the AC genotype of the A1298C polymorphism had 2.89 times higher risk of developing esophageal cancer when compared to those who had the AA genotype (P = 0.033). It was determined that individuals who had the 1298 CC genotype were not at higher risk of developing esophageal cancer when compared to those with the AA genotype (P = 0.863). It was concluded that individuals who had the TT genotype of the C677T polymorphism were not at higher risk of developing gastric and esophageal cancers when compared to those who had the 677CC genotype (P > 0.05). There was no difference in terms of the life spans of the patients with regards to the genotypes (P > 0.05). The results showed that the A1298C polymorphism on the MTHFR gene can be a risk factor for gastric and esophageal cancer in eastern Turkey. These polymorphisms may have no effect on the life spans of the patients.
In recent years home health care units became even more important after the gradual increase in the elderly population and injuries due to accidents. This study can help to provide home health care units in a more effcient manner by educating the staff and relatives who take care of the patients.
AIM: To investigate the relationship between paracetamol and expression levels of cyciooxygenase-2, cyclin B, cell viability and apoptosis in glioblastoma cell line. MATERIAL and METHODS: The A172 glioblastoma cells were treated with different concentrations of paracetamol and phosphate buffer saline as a vehicle for 24, 48, and 72 hours. Cell viability was detected by MTT. Bax, procaspase 3, COX-2 and Cyclin B expressions were detected using Western blotting. RESULTS: A paracetamol treatment of 0.5 mg/mL for 24, 48, and 72 hours led to a 14%, 31%, and 37% decrease in cell viability. The expression of COX-2 and cyclin B levels decreased by 36% and 52% respectively, after treatment with 0.5 mg/mL paracetamol. Treatment with 0.5 mg/mL and 1 mg/mL paracetamol significantly induced the expression of cleaved caspase 3, procaspase 3 and Bax proteins compared to the control group (60%, 40%, 21%, %100, 18%, 17%, respectively). CONCLUSION: The results of our study showed that paracetamol has antitumoral effects on glioblastoma cells and this activity was induced by different signaling pathways.
Objective: In recent years, paracetamol has been shown to have toxic effects on the kidneys. Sialic acid (SA), an important component of the cell membranes, increases in many pathological conditions. This study aimed to investigate the effects of different doses of paracetamol on the kidney tissue and serum total SA (TSA) and lipid-bound SA (LSA) levels. Materials and Methods: A total of 5 different groups were formed, with 8 rats in each group; 20 and 500 mg/kg/intraperitoneal paracetamol was applied to the groups once daily for 1 and 3 days, respectively. Renal pathology was evaluated with hematoxylin and eosin. TSA/LSA levels and urea/creatinine levels were measured from the blood samples taken from the rats. Results: TSA levels were significantly higher in the groups in which paracetamol was administered in a single dose and 500 mg/kg dose for 3 days than control (p<0.05 and p<0.001). LSA levels were significantly higher in the groups that received 1 and 3 doses of 500 mg/kg/day and 3 doses of 20 mg/kg than control (p<0.05, p<0.001, and p<0.05). Conclusion: SA levels may be a specific marker for kidney damage because of the increase in the SA levels in direct proportion to this level of renal degeneration. Cite this article as: Öksüz E, Buğday MS, Demir F, Ekin S, Arıhan O, Oto G. Serum Total Sialic Acid and Lipid-linked Sialic Acid May Be the New Potential Biomarkers in Paracetamol Nephrotoxicity. Turk J Nephrol 2020; 29(4): 273-8.